Novel drug delivery systems targeting oxidative stress in chronic obstructive pulmonary disease: a review

Xu, You; Li, Hongmei; Song, Lei

doi:10.1186/s12951-020-00703-5

Cited by 58 publications

(39 citation statements)

References 179 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CS-induced mitochondrial oxidative stress amplifies airway inflammation and airway mucus hypersecretion and is closely associated with COPD progression [28,29]. Antioxidants are beneficial in COPD as they inhibit the inflammatory response [30].…”

Section: Discussionmentioning

confidence: 99%

Mitochondrial‐Targeting Antioxidant SS‐31 Suppresses Airway Inflammation and Oxidative Stress Induced by Cigarette Smoke

Yang

Zuo

Wang

et al. 2021

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

This study investigated whether the mitochondrial-targeted peptide SS-31 can protect against cigarette smoke- (CS-) induced airway inflammation and oxidative stress in vitro and in vivo. Mice were exposed to CS for 4 weeks to establish a CS-induced airway inflammation model, and those in the experimental group were pretreated with SS-31 1 h before CS exposure. Pathologic changes and oxidative stress in lung tissue, inflammatory cell counts, and proinflammatory cytokine levels in bronchoalveolar lavage fluid (BALF) were examined. The mechanistic basis for the effects of SS-31 on CS extract- (CSE-) induced airway inflammation and oxidative stress was investigated using BEAS-2B bronchial epithelial cells and by RNA sequencing and western blot analysis of lung tissues. SS-31 attenuated CS-induced inflammatory injury of the airway and reduced total cell, neutrophil, and macrophage counts and tumor necrosis factor- (TNF-) α, interleukin- (IL-) 6, and matrix metalloproteinase (MMP) 9 levels in BALF. SS-31 also attenuated CS-induced oxidative stress by decreasing malondialdehyde (MDA) and myeloperoxidase (MPO) activities and increasing that of superoxide dismutase (SOD). It also reversed CS-induced changes in the expression of mitochondrial fission protein (MFF) and optic atrophy (OPA) 1 and reduced the amount of cytochrome c released into the cytosol. Pretreatment with SS-31 normalized TNF-α, IL-6, and MMP9 expression, MDA and SOD activities, and ROS generation in CSE-treated BEAS-2B cells and reversed the changes in MFF and OPA1 expression. RNA sequencing and western blot analysis showed that SS-31 inhibited CS-induced activation of the mitogen-activated protein kinase (MAPK) signaling pathway in vitro and in vivo. Thus, SS-31 alleviates CS-induced airway inflammation and oxidative stress via modulation of mitochondrial function and regulation of MAPK signaling and thus has therapeutic potential for the treatment of airway disorders caused by smoking.

show abstract

Section: Discussionmentioning

confidence: 99%

Mitochondrial‐Targeting Antioxidant SS‐31 Suppresses Airway Inflammation and Oxidative Stress Induced by Cigarette Smoke

Yang

Zuo

Wang

et al. 2021

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

show abstract

“…Oxidative stress is an important driver for the pathophysiology of obstructive airway diseases ( Figure 2 ), which suggests that antioxidants may be effective therapeutics [ 95 ]. Therefore, some strategies target systemic and local oxidative stress using antioxidants/redox-modulating agents, or boost the endogenous levels of antioxidants.…”

Section: Novel Inhaled Medicines For Obstructive Airway Diseasesmentioning

confidence: 99%

Inhaled RNA Therapeutics for Obstructive Airway Diseases: Recent Advances and Future Prospects

Thakur

Zhang

et al. 2021

Pharmaceutics

Self Cite

View full text Add to dashboard Cite

Obstructive airway diseases, e.g., chronic obstructive pulmonary disease (COPD) and asthma, represent leading causes of morbidity and mortality worldwide. However, the efficacy of currently available inhaled therapeutics is not sufficient for arresting disease progression and decreasing mortality, hence providing an urgent need for development of novel therapeutics. Local delivery to the airways via inhalation is promising for novel drugs, because it allows for delivery directly to the target site of action and minimizes systemic drug exposure. In addition, novel drug modalities like RNA therapeutics provide entirely new opportunities for highly specific treatment of airway diseases. Here, we review state of the art of conventional inhaled drugs used for the treatment of COPD and asthma with focus on quality attributes of inhaled medicines, and we outline the therapeutic potential and safety of novel drugs. Subsequently, we present recent advances in manufacturing of thermostable solid dosage forms for pulmonary administration, important quality attributes of inhalable dry powder formulations, and obstacles for the translation of inhalable solid dosage forms to the clinic. Delivery challenges for inhaled RNA therapeutics and delivery technologies used to overcome them are also discussed. Finally, we present future prospects of novel inhaled RNA-based therapeutics for treatment of obstructive airways diseases, and highlight major knowledge gaps, which require further investigation to advance RNA-based medicine towards the bedside.

show abstract

“…Nanoparticles developed by polymeric materials such as PLGA, PLA, poly(ethylene glycol)-poly(ε-caprolactone) (PEG-PCL), PLA-PEG, and some others have been studied exclusively as nanocarriers for the systematic delivery of drug molecules and biomolecules for the antiviral and other disease treatment ( Figure 1 ). [ 68–72 ] Previously, Li et al developed a unique cocktail therapeutic strategy containing biodegradable polymeric nanoparticles for antiviral treatment. [ 73 ] They developed this PEG-PLA-based cocktail nanoparticles to encapsulate HIV-1 entry inhibitor and conjugate with reverse transcriptase inhibitor, resulting in strong virucidal effects against HIV-1.…”

Section: Polymer-based Nano-therapies For Respiratory Injury Treatmentmentioning

confidence: 99%

“…(A) Different nanoparticles used to deliver antioxidants in chronic obstructive pulmonary disease (COPD) treatment. Reprinted from Xu et al [ 68 ] Owing to some advantages of nanocarrier systems like small size, high stability, targeted deposition, sustained release, biodegradation, and reduced dosing frequency, they can be used to integrate and deliver hydrophobic and hydrophilic drugs in COPD treatment. Some of the promising novel DDS for COPD treatment include polymeric nanoparticles, micelles, dendrimers, microspheres and microparticles, nanoemulsion, lipid nanoparticles, and liposomes.…”

Section: Polymer-based Nano-therapies For Respiratory Injury Treatmentmentioning

confidence: 99%

Polymer-based nano-therapies to combat COVID-19 related respiratory injury: progress, prospects, and challenges

Rana

2021

Journal of Biomaterials Science, Polymer Edition

View full text Add to dashboard Cite

The recent coronavirus disease-2019 (COVID-19) outbreak has increased at an alarming rate, representing a substantial cause of mortality worldwide. Respiratory injuries are major COVID-19 related complications, leading to poor lung circulation, tissue scarring, and airway obstruction. Despite an in-depth investigation of respiratory injury’s molecular pathogenesis, effective treatments have yet to be developed. Moreover, early detection of viral infection is required to halt the disease-related long-term complications, including respiratory injuries. The currently employed detection technique (quantitative real-time polymerase chain reaction or qRT-PCR) failed to meet this need at some point because it is costly, time-consuming, and requires higher expertise and technical skills. Polymer-based nanobiosensing techniques can be employed to overcome these limitations. Polymeric nanomaterials have the potential for clinical applications due to their versatile features like low cytotoxicity, biodegradability, bioavailability, biocompatibility, and specific delivery at the targeted site of action. In recent years, innovative polymeric nanomedicine approaches have been developed to deliver therapeutic agents and support tissue growth for the inflamed organs, including the lung. This review highlights the most recent advances of polymer-based nanomedicine approaches in infectious disease diagnosis and treatments. This paper also focuses on the potential of novel nanomedicine techniques that may prove to be therapeutically efficient in fighting against COVID-19 related respiratory injuries.

show abstract

Novel drug delivery systems targeting oxidative stress in chronic obstructive pulmonary disease: a review

Cited by 58 publications

References 179 publications

Mitochondrial‐Targeting Antioxidant SS‐31 Suppresses Airway Inflammation and Oxidative Stress Induced by Cigarette Smoke

Mitochondrial‐Targeting Antioxidant SS‐31 Suppresses Airway Inflammation and Oxidative Stress Induced by Cigarette Smoke

Inhaled RNA Therapeutics for Obstructive Airway Diseases: Recent Advances and Future Prospects

Polymer-based nano-therapies to combat COVID-19 related respiratory injury: progress, prospects, and challenges

Contact Info

Product

Resources

About